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HERIANSYAH ET AL.: Ox-LDL, Lysophospatidy Choline Platelet Activating Factor, IL-6 Expression Level
and Foam Cell Number with Darappabdib Treatment in Early Development of Atherosclerosis: In Vivo Study for
Type 2 Diabetes Mellitus Model. Background: Insulin resistance in type 2 Diabetes Melitus (T2DM) is an extensive
tissue damage condition due to vascular inflammation and oxidative stress. Lp-PLA2 has an antiinflammatory role as
it hydrolyze atherogenesis mediators such as ox-LDL and platelet activating factor (PAF) and produces
lysophosphatidylcholine (LysoPC) and oxidized fatty acid that have pro-inflammatory, proliferative and pro-atherogenic
effect. Methods and results: This study aimed to discover the expression of ox-LDL level, LysoPC, PAF, IL-6 and
foam cell numbers in aorta of T2DM in vivo model with darapladib treatment. True experimental laboratory and only
post test with control group design using 30 Spraque Dowley rats that is divided into 3 main groups: normal, T2DM,
and T2DM with the darapladib administration group. Each group consisted of 2 serials treatment time:
8-weeks and 16-weeks treatment groups. Parameter measured was IL-6, oxidized LDL and PAF, LysoPC, IL-6, foam
cells and also blood glucose, lipid profile, and insulin plasma level. ANOVA test results showed that darapladib were
significantly (p=0.000) lowering ox-LDL level, LysoPC, PAF, IL-6 expression and foam cells number in the aorta on
T2DM in vivo model. Conclusions: This study concludes that dalapladib proved to have a role as anti atherogenesis
on T2DM model. (J HK Coll Cardiol 2016;24:64-73)
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Introduction
Today, cardiovascular disease (CVD) remains as
a serious global health problem and has become the
leading cause of death in both developed and developing
countries. CVD incidence in Indonesia turned out to be
much higher than the other developed countries with
cases number is 150.8 compared to 80.5 in the United
States and 31.2 per 100,000 population in Japan. CVD
death rate in Indonesia reaches 243,048 or 17.05% of
total deaths. This condition puts CVD as the first cause
of death from 20 leading causes of death in Indonesia.1
Atherosclerosis is the most common cause of CVD,
including coronary heart disease (coronary artery
disease/CAD), cerebrovascular disease (stroke) and
peripheral blood vessel diseases (peripheral artery
disease /PAD).2
Type 2 Diabetes mellitus (T2DM) is one of major
classical risk factors for atherosclerosis. 3 Clinical
condition with insulin resistance and T2DM is a
condition of an extensive tissue damage due to vascular
inflammation and oxidative stress.4 Hyperglycemia that
occurred in DM type 2 increase Reactive Oxygen
Species (ROS) production.5 Enzymatic activity and
lipoprotein phospholipase A2 (Lp-PLA2) expression
have been studied as a biomarker of CVD risk in people
with CAD and healthy individual.6 The understanding
about Lp-PLA2 role in the cardiovascular disease
pathophysiology remains controversial and far from well
established. Lp-PLA2 antiinflammatory role is
demonstrated by this enzyme ability to hydrolyze
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mediators, such as ox-LDL and platelet activating
factor (PAF), that could potentially have a role in
atherogenesis. At the same time, hydrolysis products of
these molecules that are mediated by Lp-PLA2, such as
lysophosphatidylcholine (LysoPC) and oxidized fatty
acid, have pro-inflammatory, proliferative and proatherogenic effect.
In the last decade, a new pharmacological therapy
for atherosclerosis, which actively, selectively, and
reversibly inhibit Lp-PLA2 is being developed and the
result is darapladib. Darapladib is a substance that
hydrolyzes Lp-PLA2 substrate. Darapladib forms noncovalent bonds and reversibly with human recombinant
Lp-PLA2. Darapladib is lipophilic and has good
membrane permeability. Darapladib reduce caspase-3
and caspase-8 activity, also inhibits macrophage
apoptosis induced by ox-LDL.
Several studies stated that darapladib show
significant results in inhibiting atherosclerosis
process, 7 both in vitro and in vivo experiments. 8,9
Positive results are also shown in a trial study in
patients who undergoing carotid endarterectomy.10
However, there are several opinions regarding
darapladib function as atherosclerosis treatment,
because some clinical trials show negative results of
darapladib usage in reducing mortality from
cardiovascular disease, myocardial infarction, or
stroke.11 Based on that facts, the aim of this study is
to determine the expression ox-LDL levels, LysoPC,
PAF, IL-6 and foam cell number in aorta using in vivo
T2DM model with darapladib treatment.
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Materials and Methods
Study Group
This study used 4 weeks old male Sprague
Dawley Rats and weigh around 150-200 grams as animal
model. Samples were obtained from Bogor Agricultural
University, Bogor, Indonesia. Samples were divided into
three groups; normal group (N); type 2 DM model
groups (DM) which fed with High Fat Diet (HFD) and
given Streptozotocin (STZ) injection intraperitoneal low
dose 35 mg/kgBW, and type 2 DM model with
darapladib administration group (DMDP). Each group
was divided into two serial time, 8 weeks (early phase)
and 16 weeks (late phase). Darapladib was obtained from
Glaxo Smith Kline. Samples were given darapladib via
oral 20 mg/kgBW once per day with duration based on
time serial groups. In short, there were 6 groups in total.
N8 and N16 for normal groups (8 and 16 weeks), DM8
and DM16 for T2DM model groups (8 and 16 weeks),
and DMDP8 and DMDP16 for T2DM model with
darapladib administration groups (8 and 16 weeks).
Normal rats food contained 3.43 total energy
calories (kcal/g) (67% carbohydrate, 21% protein, and
12% fat), while HFD contained 5.29 total energy calorie
(kcal/g) (58% fat, 17% carbohydrate, and 25% protein).
Each kilogram of vitamins and minerals mixture
contained 2000000 IU Vitamin A, 400000 IU Vitamin
D3, 0.8 grams Vitamin B2, 300 units Vitamin E, 0.4
grams Vitamin K, 1 gram calcium pantothenate, 4 grams
Nicotinamide, 2.4 gram Vitamin B12, 60 grams Choline
Chloride, 300 grams Calcium, 2.75 grams Manganese,
0.1 grams Iodine, 3 grams Iron, 6 grams Zinc, 0.8 grams
Copper, and 0.18 grams Cobalt.12 30 grams food were
given for each rat everyday. Parameter measurement was
done at the Central Laboratory of Biological Sciences,
Brawijaya University, Brawijaya University, Malang,
Indonesia. Slicing and staining samples were done in
the Pathological Anatomy Laboratory, Faculty of
Medicine, University of Brawijaya, Malang, Indonesia

Blood Glucose Measurement
STZ 20 mg/kgBW was administered before the
first measurement of blood glucose to induce type 2
diabetes mellitus. Type 2 diabetes mellitus was diagnosed
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after blood glucose level measurement using GlucoDR
blood glucose test meter (All Medicus Co. Ltd, Dongangu, Anyang-si, Korea). Type 2 diabetes mellitus
was diagnosed after obtaining blood glucose levels
>200 mg/dL in rats.

Lipid Profile Levels Measurement
Lipid profiles (total cholesterol, HDL (High
Density Lipoprotein), and LDL (Low Density
Lipoprotein)) were measured in rat blood serum using
EnzyChromTM kit.

Insulin Resistance Measurement
Insulin in rat's blood plasma were measured using
Rat INS (insulin) ELISA kit (Cat. No. E-EL-R2466).
The obtained results are still in ng/mL units. Plasma
insulin levels were converted into IU / L. WHO formula
were used by dividing the result with 0.0347, as 1 IU is
equivalent with 0.0347 mg/L.13 Insulin resistance can
be measured with HOMA-IR (homeostatic model
assessment-insulin resistance) formula especially in rats,
which required some data, such as fasting glucose and
plasma insulin levels by the following formula:14
HOMA-IR =

FBS x FINS
14,1

Explanation:
HOMA-IR : Homeostatic Model Assessment-Insulin
Resistance
FBG
: Fasting Blood Glucose (mmol/L)
FINS
: Fasting Insulin Plasma (µgU/mL)
Interpretation of HOMA-IR calculation in rats is
if the result >1,716 then it can be categorized as insulin
resistance with 83.87% sensitivity and 80.56%
specificity (95% confidence interval).15

IL6 Expression Measurement
IL-6 was measured using immunofluorescence.
Aortic tissues were previously fixed with PHEMO
buffer (68 mM PIPES, 25 mM, HEPES, pH 6.9,
15 mMEGTA, 3 mM MgCl2, 10% [v/v] dimethyl
sulfoxide containing 3.7% formaldehyde and 0.05%

October 2016

66

EFFECT OF DARAPLADIB IN ATHEROGENESIS DEVELOPMENT

glutaraldehyde), then were processed by
imumunofluoresence double labeling with anti-rat
antibody Lp-PLA2 using rhodamin secondary antibody
and anti-rat antibody IL-6 using fluorescein
isothiocyanate (FITC) secondary antibody (BIOS Inc.,
Boston, MA, USA). These parameter was observed using
confocal laser scanning microscopy (Olympus
Corporation, Tokyo, Japan) and was quantitatively
analyzed using Olympus FluoViewsoftware (version
1.7A; Olympus Corporation).

Ox-LDL Measurement
Ox-LDL was measured using rats aorta tissue as
samples. The rats had been fasted a day before the sample
obtained. Ox-LDL level was measured by Sandwich
ELISA method using Rat Ox-LDL ELISA kit (Cat.
No. E-EL-R0710). The first step was antigen coating,
100 µgL standard and sample were put into well that are
coated with antibody before then incubated in 37oC for
90 minutes. Residual antigen that was not bound with
antibody were disposed. After that, add 100 µgL Biotinantibody into each well. Incubated each well in 37oC
for 1 hour. The fluid in well was aspirated and washed
by wash buffer for 3 times. Next, 100 µgL HRP avidin
was added into each well and incubated in 37oC for 30
minutes. Repeat the aspiration and washing process 5
times. Add 90 µgL TMB substrate into each well then
incubated in 37oC for 15 minutes in light-free area.
50 µgL stop reaction was added to stop the reaction.
After 5 minutes read by ELISA reader at a wavelength
of 450 nm.

LysoPC Measurement
The used samples were serum and rat's aorta
homogenates. The used tool was 6460 triplequadrupole
LCMS / MS System, Agilent Technologies, USA.
Standard LysoPC material (16:0) used was 1-palmitoyl2-Hydroxy-sn-Glycero-3-Phosphocholine (16:0), cat
85567P, lot 16LPC-79, Avanti Polar Lipids, Inc., 700
Industrial Park drive, Alabaster, Alabama 35007-9105,
USA. Standard LysoPC internal material (16: 0) used
was 1-palmitoyl (D31) -2-Hydroxy-sn-Glycero-3Phosphocholine (16: 0), paint 85567P, lot 16 LPC-79,
Avanti PolarLipids, Inc., 700 Industrial Park Drive,
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Alabaster, Alabama 35007-9105, USA. Standard LysoPC
material (18:0) used was 1-Stearoyl-2-Hydroxy-snGlycero-3-Phosphocholine(16:0), cat 85567P, lot
16LPC-79, Avanti Polar Lipids, Inc, 700 Industrial
Park Drive, Alabaster, Alabama 35007-9105, USA.
Standards calibration range used were 250-16000 ng/
mL. Dilution factors of aorta homogenates samples
16-7 for LysoPC Stearoyl was 2X. Serum sample
dilution factors was 20X, except palmitoyl (16:0)
Code 8-1 and 8-2 itwas 40X, and Stearoyl (18: 0) Code
8-1 was 80X. Standard material used specifically for
research (Research Use Only). LysoPC analysis
procedure refers to journals: Takatera A, et. al.
Blood Lysophosphatidylcholine (LPC) levels and
Characteristic Molecular Species in Neonates:
Prolonged Low Blood LPC Levels in Very Low Birth
Weight Infants. Pediatr Res:477-482, 2007.

PAF Measurement
PAF concentrations measurement in rat blood
plasma samples were conducted by competitive
ELISA method using Rat Platelet Activating Factor
ELISA kit (Cat. No. MBS722041). Competitive
ELISA begins with coating antigen. Standard and
100 µgL sample were inserted into well (to form using
PBS). Then, 50 µgL conjugate was added into each
well (except blank well) and incubated it in 37oC for
1 hour. Aspirated and washed with wash buffer
5 times. Add 50 µgL substrate A and 50 µgL substrate
B to each well and incubated for 10-15 minutes in
37oC (avoid light). 50 µgL stop solution was added
to stop reaction in each well. After 5 minutes read by
ELISA reader at a wavelength of 450 nm.

Foam Cells Measurement
Aortic tissues were prepared using a frozen
section technique and stained with hematoxylineeosin.
After aortic tissues preparation, foam cells were
measured using a microscope with 400 magnification
and dotSlide Olyvia version 2.4 software (Olympus
America Inc., Center Valley, PA, USA). Examination
and calculation of foam cells number were performed
for each 10 microscope fields after taking images of the
aortic tissues.
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Ethics
We obtained ethical approval for animal treatment
and experimental processes in this study from Animal
Care and Use Committee Brawijaya University Number
229-KEP-UB.

Statistical Analysis
One-way analysis of variance (ANOVA) test was
used to determine the effects of time series factor,
darapladib treatment, and the interaction between time
and darapladib treatment on mRNA Lp-PLA2 expresion,
ox-LDL, PAF, LysoPC, PAF and foam cells in Spraque
Dowley rats with type 2 diabetes mellitus. This analysis
was continued by post hoc test using Duncan method to
detect parameter differences in each treatment group.
SPSS software version 20 (IBM Corporation, New York,
NY, USA) was used for data analysis.

Results
Total cholesterol level range was observed from
56.560 to 123.002 (mg/dL). The highest total cholesterol
level was found in DM8 group (123.002 mg/dL).
Meanwhile, the lowest total cholesterol level was found
in N16 group (56.560 mg/dL). HDL level range was
observed from 4.958 to 35.767 (mg/dL). The highest
HDL level was found in N16 (35.767 mg/dL).
Meanwhile, the lowest HDL level was found in DM8
group (4.958 mg/dL). VLDL/LDL level range was
observed from 19.241 to 95.531 (mg/dL). The highest
VLDL/LDL level was found in DM8 group (95.531 mg/
dL). Meanwhile, the lowest VLDL/LDL level was found
in N16 group (19.241 mg/dL). Fasting glucose level
range was observed from 79.6 to 147.8 (mg/mL). The
highest fasting glucose level was found in DM16 group
(147.8 mg/mL). Meanwhile, the lowest fasting glucose
level was found in N16 (79.6 mg/mL). Plasma insulin
level range was observed from 4.664 to 40.220 (ng/mL).
The highest plasma insulin levels was found in DM16
(40.220 ng/mL). Meanwhile, the lowest plasma insulin
levels was found in N8 group (4.664 ng/mL). HOMAIR value range was observed from 0.462 to 3.789. The
highest HOMA-IR value was found in DM16 (3.789).
Meanwhile, the lowest HOMA-IR value was found in
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N16 group (0.462).
Ox-LDL level range was observed from 1.347 to
34.049 (ng/mL). The highest ox-LDL level was found
in DM16 group (34.049 ng/mL). Meanwhile, the lowest
ox-LDL level was found in N8 group (1.347 ng/mL).
ANOVA test showed that ox-LDL level was significantly
(p<0.050) influenced by time series, darapladib
treatment, and also an interaction between time series
and darabladib treatment (Figure 1A).
LysoPC level range was observed from 28.427 to
266.677 (ng/g aorta). The highest LysoPC level was
found in N8 group (266.677 ng/g aorta). Meanwhile,
the lowest LysoPC level was found in DMDP16 group
(28.427 ng/g aorta). ANOVA test showed that LysoPC
level was significantly (p<0.050) influenced by time
series, darapladib treatment, and also an interaction
between time series and darabladib treatment (Figure
1B).
PAF level range was observed from 0.726 to
1.963 (ng/mL). The highest PAF level was found in
DM16 group (1.963 ng/mL). Meanwhile, the lowest PAF
level was found in N8 group (0.726 ng/mL). ANOVA
test showed that PAF level was significantly (p<0.050)
influenced by time series, darapladib treatment, and also
an interaction between time series and darabladib
treatment (Figure 1 C).
IL-6 expression range was observed from
634.60552 to 792.131 (AU). The highest IL-6 expression
was found in DM16 group (792.131 AU). Meanwhile,
the lowest IL-6 expression was found in the DMDP8
group (634.60552 AU). ANOVA test showed that IL-6
expression was significantly (p<0.050) affected by
darapladib treatment factor. Meanwhile, time series
factor and interaction between time series and darapladib
did not significantly (p>0.050) influenced IL-6
expression (Figure 1D). Foam cells number range was
observed from 80 to 138.8 (cell). The highest foam cells
number was found in DM16 group (138.8 cells).
Meanwhile, the lowest foam cells number was found in
N8 group (80 cells). ANOVA test showed that foam cells
number was significantly (p<0.050) affected by
darapladib administration factor. Meanwhile, time series
factor and interaction between time series and darapladib
treatment did not significantly (p>0.050) influenced the
amount of foam cell (Figure 1E).
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Figure 1. The expression of ox-LDL level, LysoPC, PAF, IL-6 and foam cell numbers in aorta for each group,
(A) ox-LDL tissue, (B) LysoPC serum, (C) PAF, (D) IL-6, (E) Foam cell.
69
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Discussion
High-Fat Diet (HFD) can increase dyslipidaemia
and insulin resistance incidence that can cause a rise in
blood sugar.16 In DM model, Total Cholesterol (TC) and
Low-Density Lipoprotein (LDL) increasing level and
High-Density Lipoprotein (HDL) decreasing level were
observed. Dyslipidaemia that occur in this study lead to
insulin resistance. All cells insulin receptor can decrease
in downregulation system event due to high glucose in
blood. If these events occur continuously and
chronically, insulin receptor desensitization will happen.
It leads to a higher need blood plasma insulin to
incorporate glucose into cell tissue.
In this research, an increase in plasma insulin
levels in DM8 and DM16 groups occurred. That
conditions may increase insulin resistance incidence. By
using HOMA-IR rat formula it was found that insulin
resistance occurred in DM16 and DM8 groups (CI 95%;
sensitivity 83.87%; specificity 80.56%). DM8 group has
shown an increase in HOMA-IR value compared with
other groups, but has not been able to reach the cut-off
value. This shows that DM8 group is almost in insulin
resistance state or pre-diabetic condition. Abnormalities
in lipoprotein metabolism are also associated with type
2 diabetes and trigger atherosclerosis development.17
Glucose and lipid metabolism disorders are synergistic
in atherosclerosis development.18 In atherosclerosis,
vascular damage occurs as a result of inflammation and
oxidative stress.4,5 Metabolic disorders associated with
type 2 diabetes such as hyperglycaemia, AGEs
formation, increased FFA, and lipoprotein abnormalities
can induce vascular inflammation and promote
atherosclerosis progressivity.19
Lp-PLA2 is an enzyme that able to catalyze many
important biological reactions and allegedly played an
important role in atherosclerosis pathogenesis. Lp-PLA2
expression in this study tend to increase in type 2
diabetes condition and tend to decrease overtime
increment. This scheme shows Lp-PLA2 role in early
stages ofatherosclerosis. Darapladib administration in
this study had no significant effect on Lp-PLA2
expression. The increasing of Lp-PLA2 expression is
associated with ox-LDL level. A study shows that
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ox-LDL play an important role in atherosclerosis
pathogenesis and it is easy to form and increase in T2DM
state. 19 Ox-LDL level in this study is significantly
influenced by time series, darapladib treatment, and also
interaction between time series and darapladib treatment.
An increasing of ox-LDL level occurred in adipocytes
development, insulin resistance, and type 2 diabetes.20
LysoPC, the main products of Lp-PLA2 activity,
is a proatherogenic property of ox-LDL which can induce
proteoglycans synthesis and play an important role in
the intimal layer thickening of the endothelium. 21
LysoPC in this study is significantly infl uenced by time
series, darapladib treatment, and interaction between
time series and darapladib treatment. The increased of
Lp-PLA2 activity are also increase LysoPC levels that
are cytotoxic on blood vessels and smooth muscle
cells.22 Based on preclinical studies, darapladib is proven
to reduce atheroma which has LysoPC and some
expression of multiple genes related to macrophage and
T lymphocyte function in large enough quantities to the
plaque and necrotic core area.23 Research conducted by
Melissa et al in 2012 stated that the increased levels of
LysoPC occur at type 2 diabetes mellitus onset and
obesity condition.24
Lp-PLA2 has an anti-inflammatory role through
its ability to hydrolyze oxidized phosphatidylcholine and
PAF that are pro-inflammatory and pro-thrombotic. PAF
is a potent inflammatory agent that has a very important
role in atherosclerosis formation.25 In this study, PAF
levels were significantly (p<0.050) influenced by time
series, darapladib treatment, and interaction between
time series and darapladib treatment. Previous study
explained, darapladib and rilapladib can inhibit PAF
receptor, therefore reducing PAF biological activity, as
well as interfere with PAF biosynthesis.26
IL-6 is one of pro-inflammatory cytokine that
involved in atherogenesis. IL-6 in type 2 diabetes mellitus
condition can increase basal glucose uptake, alter insulin
sensitivity, improve adhesion molecule expression by
endothelial cells, have pro-coagulant effects on platelets,
and increase fibrinogen release by liver. In addition,
IL-6 is also capable of blocking lipoprotein lipase action
and stimulate lipolysis process.27 In this study, IL-6
expression were significantly (p<0.050) affected by

October 2016

70

EFFECT OF DARAPLADIB IN ATHEROGENESIS DEVELOPMENT

darapladib treatment. While time series factor and
interaction between time series and darapladib treatment
does not significantly affect IL-6 expression (p>0.050)
(Figure 2). Increased Lp-PLA2 expression followed by
increased expression of cytokines IL-6 in type 2 diabetes.
Ox-LDL stimulate macrophages to phagocyte
lipid, then form a foam cell that signed the ongoing
process of atherogenesis.28 This study shows that foam
cells number was significantly (p<0.050) affected by
darapladib treatment. While the time series factor as well
as the interaction between time series and darapladib
treatment does not significantly affect the amount of
foam cell (p>0.050) (Figure 3). Foam cells formation
induced glucose indicates that glucose uptake is required
by cells, namely D-glucose (which is taken up by cells)
but not L-glucose (which can not be attached to cell
membrane) which then could induce macrophage
oxidative stress.29

Figure 2. Three immunofluorescence staining result of IL-6
using Fluorescein Isothiocyanate (FITC) secondary antibody.

Figure 3. Foam cells in different treatment groups of rats: (A) normal diet group 8 weeks; (B) T2DM 8 weeks; (C) T2DM
+ darapladib (20 mg/kgBW) 8 weeks; (D) normal diet group 16 weeks; (E) T2DM 16 weeks; and (F) T2DM + darapladib
(20 mg/kgBW) 16 weeks
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Conclusion
Darapladip is Lp-PLA2 inhibitor, it is lipophilic
and has a stupendous membrane permeability. Recent
studies explained that darapladip showed significant
result in inhibiting atherosclerosis process, whether by
in vitro or in vivo test.7-9 Darapladib were significantly
affected ox-LDL level tissue, PAF plasma, IL-6
expression and foam cells number.
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